Antibody Epitope Profiling for SARS-CoV-2 Severity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an ongoing need for improved compositions and methods to address differences in immune responses to coronavirus infections, particularly in understanding how preexisting humoral memory responses against seasonal human coronaviruses contribute to the severity and outcomes of SARS-CoV-2 infections.
Innovation Solution
The disclosure provides characterization of anti-spike IgG levels in non-hospitalized convalescent individuals and ICU-hospitalized patients, demonstrating correlations with disease severity, FcγR activation, and cross-reactivity against betacoronaviruses, and proposes using epitope targeting ratios to predict severity and vaccine efficacy, tailoring treatments based on antibody profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If preexisting humoral memory responses against seasonal coronaviruses are present, then cross-reactivity against SARS-CoV-2 spike protein increases, but disease severity may be exacerbated through ADE mechanisms
Solution Approach 1:
The patent applies parameter changes by measuring and comparing antibody titers against different epitopic regions (S1 vs S2, RBD vs non-RBD) to determine the quality of the immune response. By quantifying the ratio of neutralizing to non-neutralizing antibodies, the method transforms a harmful cross-reactive response into a measurable parameter that guides clinical intervention decisions.
Solution Approach 2:
The patent implements feedback by using the measured antibody profile to inform subsequent clinical decisions. The assay results provide feedback about the patient's immune response quality, which then guides whether to administer vaccination, monoclonal antibodies, or other interventions, creating a closed-loop system that adjusts treatment based on immune status.
2Reliability
If high levels of anti-spike IgG are produced, then neutralization capacity may increase, but FcγR activation and proinflammatory mediator production increase disease severity
Solution Approach 1:
The patent segments the antibody response into distinct functional components by measuring antibodies against specific epitopic regions separately. By dividing the total anti-spike IgG into neutralizing (RBD-directed) and non-neutralizing (S2-directed) components, the method can identify and address the harmful segment without suppressing the beneficial neutralizing response.
Solution Approach 2:
The patent applies local quality by evaluating the functional quality of antibodies at specific epitopic locations rather than treating all anti-spike antibodies uniformly. The method identifies that antibodies against certain regions (S2, non-RBD) have harmful local effects through FcγR activation, while antibodies against other regions (RBD) have protective local effects through neutralization.
3Quantity of substance
If conventional antibody assays measure total anti-spike IgG, then overall immune response is quantified, but differential effects of antibodies against different epitopic regions are masked
Solution Approach 1:
The patent segments the measurement process into multiple specific assays targeting different epitopic regions. Instead of a single total IgG measurement, the method divides the assessment into separate measurements for S1-directed, S2-directed, RBD-directed, and non-RBD-directed antibodies, preserving the differential information that would otherwise be lost in aggregation.
Solution Approach 2:
The patent adds another dimension to the measurement by introducing epitope-specificity as a new measurement axis. Rather than measuring only the quantity of total anti-spike IgG, the method adds the dimension of target specificity, creating a multi-dimensional profile that captures both quantity and quality of the immune response.
Data Source
AI summary
Provided are compositions and methods for use in determining antibody profiles from individuals who have been infected, vaccinated, or both infected and vaccinated with a one or more types of coronavirus. The compositions and methods can be used for predicting severity of outcomes, or for developing and implementing medical interventions.